Hypersensitivity Pneumonitis Market is Expected to Grow at a CAGR over 4.10% from 2022 to 2030

Pune, India, May, 2023 /MRFR Press Release/- Market Research Future published a half-cooked research report on global hypersensitivity pneumonitis market. 

Hypersensitivity Pneumonitis Market Highlights

The global hypersensitivity pneumonitis market is expected to grow at a CAGR of 4.10% during forecasted period (2022-2030) and is anticipated to reach USD 1,503.50 Million by 2030. 

Hypersensitivity pneumonitis is a rare disorder pertaining to the immune system that affects the lungs and occurs due to certain organic and inorganic substances such as pollen, mold and others. These substances trigger their immune systems, causing short- or long-term inflammation, especially in a part of the lungs called the interstitium. Global hypersensitivity pneumonitis market is majorly driven by the increasing prevalence of hypersensitivity pneumonitis, and increasing patients suffering from allergies. According to the Centers for Disease Control and Prevention, in 2012, 7.8 million pediatric cases of respiratory allergies were reported. Moreover, increasing pollution, changing lifestyle and rising geriatric population have fuelled the growth of the market. Increasing healthcare spending and government support also contributed in the growth of the market. On the other hand, lack of absolute treatment may restrain the market growth.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Hypersensitivity Pneumonitis Market Research Report

Regional Analysis

The Americas commands the largest share in the global hypersensitivity pneumonitis market owing to a large patient population, high healthcare spending, and strong government support for research & development. According to the American Academy of Allergy, Asthma & Immunology, in 2013, approximately 13% of people 18 and over in the U.S. have sinusitis. Additionally, according to the Asthma and Allergy Foundation of America, in 2015, 8.2% of adults and 8.4% of children were diagnosed with hay fever. Moreover, increasing geriatric population has fuelled the growth of the market.  Europe has the second leading market in global hypersensitivity pneumonitis market which is followed by Asia Pacific. Asia Pacific is the fastest growing market for hypersensitivity pneumonitis. India and China are the major contributors for the Asia Pacific hypersensitivity pneumonitis market. A number of developing countries are present in Asia Pacific. Increasing geriatric population, presence of huge opportunity for the development of the market and increasing pollution in this region have fuelled the growth of the market. The Middle East and Africa contribute reasonably less toward the growth of global hypersensitivity pneumonitis market. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic conditions. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market owing to the strong economic conditions.

Explore In-depth Details: Hypersensitivity Pneumonitis Market Research Report

Segmentation

The global hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users.

On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis.

On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others.

On the basis of end users, the market is segmented into hospital, clinics, and others. 

Key Players

The key players for the global hypersensitivity pneumonitis market: Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Abbott (U.S.) Eli Lilly (U.S.), Bayer Cropscience Ltd. (U.S.).,  Sunpharma (India), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), Sanofi (France), and Novo Nordisk (Denmark).